Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.…
Lakefront Creates New Subscription Right Plan
Lakefront Biotherapeutics (NASDAQ: LKFT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 196 employees.
The shares were at 33.31 USD on 20 November 2026, up 3.1% over 52 weeks. Its 52-week range is 25.68 USD to 36.24 USD: the price is 8.1% below the high and 29.7% above the low.
At a market capitalisation of 2.18B USD, it trades at 2.4 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 93% for LKFT.
Lakefront Biotherapeutics reports return on equity of 9.9%, an operating margin of 57.5% and revenue down 81.5% year over year.
It holds more cash than debt, a net cash position of 2.23B EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 30.76 USD is 7.7% below the current price. The next earnings report is expected on 24 February 2027.